A role for transient infections in the aetiology of venous thrombosis (VT) has been suggested. This study aimed to determine whether individuals who receive antibiotic treatment (as a proxy for infections) have an increased risk of first and recurrent VT and whether infections should be seen as a provoking risk factor for VT.
Summary
A role for transient infections in the aetiology of venous thrombosis (VT) has been suggested. This study aimed to determine whether individuals who receive antibiotic treatment (as a proxy for infections) have an increased risk of first and recurrent VT and whether infections should be seen as a provoking risk factor for VT.
We used the self-controlled case series method to study the risk of first VT during antibiotic prescriptions. The risk of recurrent VT during antibiotic use was estimated by of time-dependent Cox-regression. A total of 2547 patients with a first VT were included and followed for a median of 5Á9 years for recurrence (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) , in whom 114 first events occurred during antibiotic use. We found a five-fold increased risk of first VT during antibiotic treatment: [incidence-rate-ratio 5Á0; 95% confidence interval (CI), 4Á0-6Á1]. Antibiotic use was associated with a 2Á0-fold (95% CI, 1Á1-4Á0) increased risk of recurrent VT. Patients with an unprovoked first VT who used antibiotics shortly before this event, had a similar risk of recurrence as patients with a provoked first VT (adjusted hazard ratio 1Á1; 95% CI, 0Á7-1Á7). Individuals who receive antibiotics have an increased risk of first and recurrent VT and infections should be considered a provoking risk factor for VT.
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Venous thrombosis, defined as deep vein thrombosis (DVT) of the leg or pulmonary embolism (PE), is a major cause of mortality and morbidity. The incidence of venous thrombosis in the population is 1-2 per 1000 individuals per year (Naess et al, 2007) , and the cumulative incidence of recurrent venous thrombosis within 5 years after a first event is 20-25% (Prandoni et al, 1996; Hansson et al, 2000; Heit et al, 2000) . No provoking risk factor can be identified in about half of the patients with venous thrombosis. This is clinically important, as these patients are advised to use long term anticoagulant treatment by most current guidelines, depending on their risk of bleeding and preference (National Institute for Health and Clinical Excellence 2012; Kearon et al, 2016a) .
In 2006, an increased risk of venous thrombosis in patients who had a transient respiratory or urinary tract infection was observed (Smeeth et al, 2006) . The risk was highest in the first 3 months after diagnosis of an infection (Smeeth et al, 2006) . Also, as many as 36% of patients with acute venous thrombosis report, when asked, symptoms or signs of a transient infectious or inflammatory disease during the 4 weeks prior to presentation (Tichelaar et al, 2010) . This and other literature adds credence to the suggestion that transient infectious disease is a risk factor for venous thrombosis. Nevertheless, infection is currently not considered to be a provoking factor for venous thrombosis (Kearon et al, 2012) . Moreover, the influence of infection on risk of recurrence has only received anecdotal attention in the literature and little formal study (Novacek et al, 2010; Ageno et al, 2012) . The mechanism that underlies the association has, in addition to laboratory studies (Riewald et al, 2002) , only been studied in patients with sepsis (Levi & Ten Cate, 1999) .
This study aimed to determine whether individuals who receive antibiotic treatment (as a proxy for infection) have an increased risk of first and recurrent venous thrombosis. For this purpose we used two different study designs; a selfcontrolled case series (SCCS) and a prospective follow-up design. Additionally, we aimed to assess to what extent antibiotic use is a provoking risk factor for venous thrombosis, by comparing absolute risks of recurrence in patients with or without an otherwise provoked first venous thrombosis and with or without antibiotic use shortly before the first event. Addition of acute infection to the list of provoking risk factors for venous thrombosis could have substantial implications for the duration of anticoagulant treatment after an infection-associated first venous thrombosis.
Methods

Patients
Consecutive patients aged 18-70 years with a first DVT or PE were included in the Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis (MEGA) study. Details of the MEGA study have been described previously (Blom et al, 2005; Bezemer et al, 2009 ). In short, 4956 patients with an objectively identified first DVT of the leg or PE were recruited in between February 1999 and September 2004. Of these patients, 225 did not consent to participate in a follow-up study on recurrent venous thrombosis (MEGA follow-up study). Therefore, 4731 patients were followed from their first venous thrombotic event until 2008-2010 when they completed a questionnaire on recurrent venous thrombosis (Flinterman et al, 2015) . This study has been approved by the Medical Ethics Committee of the Leiden University Medical Centre, and all patients gave written informed consent.
Outcome classification first venous thrombosis
Patients with a first venous thrombotic event were identified at six anticoagulation clinics in the Netherlands (Blom et al, 2005) . The anticoagulation clinics monitor the anticoagulant therapy of all patients in a well-defined geographical area, which allowed the identification of consecutive and unselected patients with venous thrombosis. Unprovoked venous thrombosis was defined as venous thrombosis without surgery, trauma, plaster cast, pregnancy or immobilisation in the 3 months immediately before the event, prolonged travel in the 2 months immediately before the event, active malignancies in the 5 years prior the event or hormone use (oral contraceptives or hormone replacement therapy) at the time of the event. Patients who had one or more of these risk factors at time of their thrombotic event were classified as having had a provoked venous thrombosis.
Outcome classification recurrent venous thrombosis
During the same period that patients were asked to selfreport on any recurrent thrombotic events during follow-up, information about recurrences was additionally retrieved from the anticoagulation clinics and from hospital discharge letters. Furthermore, between 2007 and 2009 the vital status of all patients was acquired from the central Dutch population register . For the patients who died, the cause of death [International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) encoded] was obtained from the national register of death certificates at the Central Bureau of Statistics. Deaths due to recurrent venous thrombosis were counted as fatal recurrent events. Information from the anticoagulation clinics, hospital discharge letters, questionnaires filled in by the patients and death certificates was combined and, based on the combined information, recurrences were classified into certain and uncertain recurrences, following a previously described decision rule (Flinterman et al, 2015) . In short, reported recurrences were classified into certain recurrences when there was a discharge letter stating a diagnosis of a recurrent event based on clinical and radiological data, or when both the anticoagulation clinic and the patient reported a recurrent event at either a clearly different location than the first event or more than 1 year had passed since the first event, or when a registered death from a recurrent event at least 6 months after the first event was found.
Antibiotic exposure definition
Information on antibiotic use was obtained by linkage to the Stichting Farmaceutische Kengetallen [SFK (Dutch Foundation for Pharmaceutical Statistics)] register (http:// www.sfk.nl/english). In the Netherlands, antibiotics are only available by prescription, and over 95% of the community pharmacies in the Netherlands are represented in this register. SFK contains information about patient-specific drugs dispensed: the generic name of a drug, the Anatomical Therapeutic Chemical (ATC) classification, the date of prescription, and the number of days for which a drug was prescribed. Information from this register was available for the years 1999-2009. Linkage was based on a combination of age, sex, 4-digit postal code and vitamin K antagonist use within the first month after the initial venous thrombosis. Between 1999 and 2004, the inclusion period for the MEGA study, low molecular weight heparins (as well as direct oral anticoagulants) were not regularly prescribed for long-term anticoagulation. In total, 2547 (54%) patients of the MEGA study could be individually linked with SFK, after which MEGA patients with one or more prescriptions of antibiotics in the period 1999-2009 could be identified.
Clinically, an early presentation of PE may at first be misdiagnosed as an infection. Early symptoms of PE can be mistaken for a respiratory tract infection and antibiotics will be prescribed in such cases. This misclassification would lead to spurious associations between antibiotic use and PE: the same may be true for DVT and infections of the skin on the leg. We reduced this possibility of misclassification step by step. First, we excluded patients in whom it was likely that such misclassification had taken place, based on information of discharge letters. For example, a discharge letter stating that a patient was admitted to hospital with symptoms of shortness of breath and a tickling cough not responsive to antibiotic treatment and was diagnosed with a PE in the hospital most likely indicates misclassification. Second, we performed subgroup analyses involving patients with DVT only, PE only or PE with or without DVT, as the pathophysiology of DVT might be different from that of PE (van Langevelde et al, 2012) and as misclassification (of, for example, an acute lung infection) is likely to be less for DVT than for PE. Furthermore, we stratified results for different types of antibiotics. We expected virtually no misclassification for antibiotics prescribed for urinary tract infections. We defined three main groups of antibiotics based on the condition for which these antibiotics are most often prescribed in the outpatient setting in the Netherlands: (i) penicillins, tetracyclines and macrolides (wide range of infections); (ii) nitrofurane derivatives, sulphonamides and trimethoprim and quinolones (primarily urinary tract infections); (iii) flucloxacillin (primarily skin infections).
Design and statistical analyses
Antibiotic use and first venous thrombosis risk. We used the SCCS method to study whether patients who received antibiotic treatment had an increased risk of first venous thrombosis. The SCCS method is used to study the association between an acute event and a transient exposure using data on cases only. The method relies on intra-person comparisons in a population of individuals who have had the outcome of interest, thereby eliminating fixed confounding (Whitaker et al, 2006) . All fixed confounders that do not vary over the study periods, such as frailty or general health status, and that act proportionally on the baseline risk, are controlled for implicitly. Such confounding is hard to control for in multivariate regression analyses and in these types of analyses there will always be some unmeasured confounding. Only those patients with a first venous thrombosis and at least one prescription of antibiotic use during the observation period from February 1999 to September 2004 (inclusion period for MEGA case-control study) were included in this analysis (n = 1584).
We derived measures of the relative incidence of events during exposure to antibiotics as compared with all other observed time periods for each patient. The null hypothesis was that venous thrombotic event rates remain constant from day to day and are not affected by an acute exposure of antibiotic use. The period of exposure was defined as extending up to the end of treatment with antibiotics. Additional analyses were performed in which only the first week after the prescription of an antibiotic was considered exposed person-time. All other observation time was taken as the baseline period (i.e., without exposure). This method and the time intervals used are illustrated in Fig 1. Conditional Poisson regression was used to estimate incidence rate ratios (IRRs) [with 95% confidence intervals (CIs)] for events occurring within the period of exposure as compared with the baseline period. Subgroup analyses were performed in patients with either DVT only, PE only or PE with or without DVT and in patients with either a provoked or unprovoked first event or a provoked first event not related to recent hospitalisation. Additionally, IRRs were estimated for the three types of antibiotics.
Antibiotic use during follow-up and subsequent recurrent venous thrombosis risk. In a cohort study design we studied whether antibiotic use was associated with recurrent venous Risk periods in the self-controlled case series analysis. As shown in this example, the effect of each infectious stimulus was analysed separately for the outcome of venous thrombosis. All individuals had at least one exposure to the stimulus (prescription of antibiotic), and had at least one venous thrombotic event. Risk periods were defined as total period of antibiotic drug use (not drawn to scale), which was further divided into the first week of use.
Risk of Venous Thrombosis During Antibiotic Use
ª 2017 John Wiley & Sons Ltd thrombosis. Duration of follow-up was estimated as the time at risk from the date of the index (first) thrombotic event to the end of follow-up. The end of follow-up was defined as the date of a recurrent event and in the absence of a recurrence, the date of filling in the follow-up questionnaire. If a patient did not fill in a questionnaire, they were censored at the last date they were known to be recurrence-free. This could be date of death (n = 49), date of emigration (n = 1), date of the last visit to the anticoagulation clinic (n = 264) or the last time known to be recurrence free from information of the MEGA case-control study (n = 198). Details of the end of follow-up assessment have been described previously (Flinterman et al, 2015) . In the analyses we considered certain recurrent events only (n = 367). Patients with uncertain recurrent events (n = 120) were censored from this uncertain recurrent event onwards.
Incidence rates of recurrent venous thrombosis were estimated as the number of events over the accumulated followup time and with person time split for periods with and without antibiotic treatment, without a wash-out period. This means that a patient with antibiotic use during followup contributes with one or several observation periods of exposed and non-exposed person-time. The association between antibiotic use and recurrent venous thrombosis was estimated by means of Cox regression analysis with antibiotic use entered as a time-varying variable. Hazard ratios with corresponding 95% CIs were estimated and corrected for age and sex. Exposure to antibiotics was set at the total period of antibiotic use by the patient and additionally limited to the first week of antibiotic use.
Antibiotic use shortly before first venous thrombosis and risk of recurrent venous thrombosis. Lastly, we estimated the absolute risk of venous recurrence in patients with first venous thrombosis who had used antibiotics shortly (within 3 months) before their first event. A transient provoking factor for venous thrombosis is defined in the literature as an environmental factor that occurred shortly (between 2 and 3 months) before the event, that resolves after the event and is associated with a decline in subsequent venous thrombosis risk (Kearon et al, 2016b) . To assess to the extent to which antibiotic use is a provoking factor according to this definition, we estimated absolute risks of recurrence in patients with or without an otherwise provoked first venous thrombosis and with or without antibiotic use within 3 months prior to the first event. Hazard ratios were estimated to compare the risks of recurrence between these groups. Results were adjusted for age and sex because male sex is a strong predictor of venous recurrence (Kyrle et al, 2004; Christiansen et al, 2005) and possibly, age as well (Kearon et al, 1999; Hansson et al, 2000; Heit et al, 2000; Eischer et al, 2009) .
All statistical analyses were performed using SPSS, version 20.0 (IBM Corp., Armonk, NY, USA) and Stata, version 12 (Stata Corp., College Station, TX, USA).
Results
A total of 2547 patients could be linked to the SFK data register and were included for analyses. Characteristics of these patients at the first venous thrombosis are shown in Table I . Median age of the patients was 51 years and 1197 (47%) patients were male. Most first events were DVT (59%) and most first events were provoked (68%). Baseline characteristics did not differ between those who could and could not be linked to the SFK register (Table I) .
Antibiotic use and first venous thrombosis risk
A total of 1584 patients with a first venous thrombotic event had at least one prescription of antibiotics in the period from February 1999 to September 2004 (5850 prescriptions in total). These patients were included in the SCCS analysis. One hundred and fourteen patients (7%) had their first event during a period of antibiotic use. During the aggregated period of antibiotic use the risk of a first event was five-fold increased (IRR 5Á1; 95% CI, 4Á1-6Á3) as compared with periods without antibiotic use (Table II) . When limiting exposure to the first week of antibiotic use the IRR was 5Á3 (95% CI, 4Á2-6Á6). To minimise misdiagnosis of PE or DVT as an infection, we excluded 13 individuals in whom misclassification certainly played a role, based on information from discharge letters. After this exclusion, the overall risk of venous thrombosis was 4Á5-fold increased during antibiotic use (IRR 4Á5; 95% CI, 3Á6-5Á6). For DVT only, the IRR was 3Á2-fold increased (95% CI, 2Á2-4Á7). Incidence rate ratios for the three types of antibiotics are shown in Table III . There were 1357 patients who had at least one prescription of antibiotics for a wide range of infections, 218 patients who had at least one prescription of antibiotics mainly used for skin infections and 622 patients had at least one prescription of antibiotics mainly used for urinary tract infections. These groups could overlap because some patients received several types of antibiotics. The risk of venous thrombosis was increased almost 5-fold (IRR 4Á7; 95% CI, 3Á6-6Á1) for the first group of antibiotics with a substantial difference between DVT (IRR~3) and PE (IRR~7). For antibiotics used mainly for infections of the skin the risk of venous thrombosis was about 4-fold (IRR 4Á1; 95% CI, 1Á7-10Á0) increased, with roughly similar risks for DVT and PE. For antibiotics used mainly for urinary tract infections the risk of both DVT and PE was three-fold increased, with IRRs of 3Á2 (95% CI, 1Á9-5Á6) and 3Á0 (95% CI, 1Á3-6Á8) for DVT and PE, respectively. IRRs were generally lower for patients with an unprovoked first venous thrombosis as compared with patients with a †13 patients for whom misclassification was certain, based on information from discharge letters, were excluded from these analyses. 
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First week of antibiotic use Antibiotic use during follow-up and subsequent recurrent venous thrombosis risk
Of 2547 patients included in this analysis 367 had recurrent thrombosis, yielding an incidence rate of 29Á1/1000 personyears (95% CI, 26Á3-32Á3). During follow-up 1401 patients (55%) had at least one prescription of antibiotics. The incidence rate of recurrent venous thrombosis was 56Á2/1000 person-years (95% CI, 29Á2-108Á0) during antibiotic use, while it was 28Á8/1000 person-years (95% CI, 25Á9-31Á9) during periods without antibiotic use (Table IV) . The recurrence risk was two-fold increased during the use of antibiotics (hazard ratio 2Á0; 95% CI, 1Á1-4Á0) after adjustment for age and sex. During the first week of antibiotic use, the risk was 2Á9-fold (95% CI, 1Á4-6Á1) increased.
Antibiotic use shortly before first venous thrombosis and risk of recurrent venous thrombosis
We estimated incidence rates of recurrent venous thrombosis separately for patients with and without antibiotic use within the 3 months prior to their otherwise provoked or unprovoked first thrombotic event (Table V) . Recurrence rates were increased for patients with an unprovoked first venous thrombosis, either with or without prior antibiotic use, as compared with patients with a provoked first event. However, patients who had a first unprovoked event but had used antibiotics did not have an increased rate of recurrence as compared with those who had a provoked first event without antibiotic use after taking differences in age and sex into account, as shown by an age-and sex-adjusted hazard ratio of 1Á1 (95% CI, 0Á7-1Á7).
Discussion
Summary of findings
We found an increased risk for both first and recurrent venous thrombosis during periods of antibiotic use. Relative risks appeared highest during the first week of antibiotic use for both first and recurrent venous thrombosis. IRRs for a first venous thrombotic event ranged from three to seven. Given that symptoms of venous thrombosis might mimic an infection, we took several steps to reduce possible misclassification. After exclusion of patients for whom misclassification was likely and after including patients with DVT only (for whom we expect less misclassification than in patients with PE) we still found a 3-fold increased risk of venous thrombosis, indicating that our results are robust. For antibiotics prescribed mainly for urinary tract infection, for which we expect no misclassification, we also found a 3-fold increased risk of both DVT and PE. We found a two-fold increased recurrence risk for patients with a history of venous thrombosis using antibiotics as compared with those who did not. Patients with an 'unprovoked' first venous thrombosis who had used antibiotics shortly before the event had a similar risk of recurrence as patients with a provoked first venous thrombosis after taking age and sex differences into account.
Previous studies
To our knowledge, no studies are available addressing the risk of recurrent venous thrombosis during or after infectious disease. In contrast, several studies have been published that showed that the risk of first venous thrombosis is increased after infections and inflammatory diseases (Smeeth et al, 2006; Tichelaar et al, 2010; Clayton et al, 2011; Ribeiro et al, 2012; Schmidt et al, 2012) . Our study confirms the findings from these studies.
In a large registry study from Denmark, over 15 000 cases with venous thrombosis were matched to controls from the general population (Schmidt et al, 2012) . Within 3 months after a hospital-diagnosed infection the risk of venous thrombosis was increased three-fold as compared with patients without infection (IRR 3Á3; 95% CI, 2Á9-3Á8). In the community, the risk of venous thrombosis was also almost three-fold increased after antibiotic treatment (IRR 2Á6; 95% CI, 2Á5-2Á8), with higher risks for antibiotics prescribed for both respiratory tract and skin or soft tissue infections than for antibiotics prescribed for urinary tract infections. The associations were strongest within the first 2 weeks and gradually declined thereafter. These results are quite similar to our findings. We previously showed in the MEGA case-control study that selfreported pneumonia substantially increased the risk of venous thrombosis in the subsequent year (OR 4Á8; 95% CI, 3Á6-6Á2) after adjustment for many confounding factors (Ribeiro et al, 2012) . It was shown that the association could only partially be explained by a concurrent period of immobilization or lifestyle. In a large case-control study based on a general practice database from the UK, 4Á0% of DVT cases were reported to have a respiratory infection in the year before the index date as opposed to 2Á3% in the controls (Clayton et al, 2011 ). An increased risk of DVT was found in the month following infection (OR 2Á6; 95% CI, 1Á6-4Á3). In this study urinary tract infections were less strong risk factors for venous thrombosis than respiratory infections. There was only weak evidence for an association with subsequent DVT and no evidence of an increased risk of PE following urinary tract infections. The authors suggested that these latter findings might be explained by small patient numbers.
Misclassification of symptoms of either DVT or PE as an infection might have affected all of the abovementioned studies. The study based on the UK general practice database (Clayton et al, 2011) reduced possible misclassification by excluding patients with a respiratory infection in the month before PE. The other studies were not able to reduce any misclassification. People with and without diagnosed infections probably are different in other aspects besides their infection, therefore comparison between individuals could be misleading and correction for potential confounders is crucial. In the large registry study from Denmark (Schmidt et al, 2012 ) correction for confounders affected results considerably and the covariate with the most influence was a measure of frailty or immobility. Although most of the abovementioned studies corrected for many potential confounders, residual confounding remains possible. Smeeth et al (2006) solved part of the problem caused by fixed confounders by performing a self-controlled case study. The risk of both DVT and PE was increased two-fold during the first week of a urinary tract infection. During the first week of a respiratory tract infection the risk of DVT was also increased two-fold (IRR 1Á9; 95% CI, 1Á5-2Á4). Our relative risks are somewhat higher than the results reported by Smeeth et al (2006) (IRR~3) . This may be explained by our inclusion of objectively identified thrombotic events only, while the events included in the study reported by Smeeth et al (2006) were taken from an electronic database without verification of events.
Interpretation of our findings
Several explanations are possible for our findings of an increased risk of venous thrombosis during antibiotic use: (i) infections increase the risk through a systemic effect on the coagulation system; (ii) infections increase the risk through immobilisation/bed rest; or (iii) the antibiotics themselves have a direct effect on the risk of venous thrombosis. It has been reported that oral application of some of antibiotic drugs (i.e. macrolides, penicillins) can lead to overgrowth of Gram-negative bacteria in the gut (Dethlefsen & Relman, 2011) . This shift has been causally associated with entrance of Gram-negative bacteria into the blood stream and ultimately increased circulatory levels of lipopolysaccharides inducing a pro-coagulant state (Beutler & Rietschel, 2003; Reitsma et al, 2003; Cani et al, 2009 ). This could lead to the hypothesis that some antibiotics might contribute to the development of clinical venous thrombosis by changing the gut microbiome. However, we have seen increased risks of venous thrombosis for all types of antibiotics and side effects are rarely a class-effect, suggesting that this theory does not explain our findings. We observed higher thrombosis risks for all types of venous thrombosis, including unprovoked venous thrombosis in which patients reported no immobilisation >3 days prior to thrombosis and provoked venous thrombosis with exclusion of patients admitted to hospital in the 3 months prior to thrombosis. Furthermore, we observed higher thrombosis risks for all types of antibiotics, amongst others antibiotics prescribed for urinary tract infections, for which we expect patients to take less bed rest. Therefore, immobilisation as the sole explanation for our findings is improbable. This suggests that the first explanation, i.e. infections increasing the risk of venous thrombosis by a systemic effect on the coagulation system, is the most likely (Violi et al, 2014) . Additional proof that infections cause thrombosis comes from associations between infection and subsequent thrombosis in the same specific site, reported for various morbidities, e.g. Lemierre syndrome and cerebral (Korathanakhun et al, 2015; Johannesen & Bodtger, 2016; Yildiz et al, 2016) .
Strong points
The strong points of this study are that we used the SCCS method. By using this method, confounding by fixed factors, such as the above-mentioned frailty, is accounted for. Requirements for the use of a SCCS method are that the association concerns an acute event and a transient exposure, which was the case for our research question. Furthermore, the probability of exposure must not be altered by a previous event. We can safely assume that the probability of antibiotic use is not altered by a previous venous thrombotic event. Secondly, as exposure to antibiotic treatment was recorded independently of the subsequent venous thrombotic event, biased ascertainment of exposure does not play a role. Another strong point of this study is that both first and recurrent venous thrombotic events were objectively confirmed. Other studies relied on thrombotic events reported in electronic databases, often without diagnostic information. In our study, possible recurrences were classified into certain recurrences and uncertain recurrences and only certain recurrences were taken into account. The main purpose of this was to distinguish extensions of a first event from truly new thrombosis. We are the first to study risk of recurrent venous thrombosis during periods of antibiotic use and to study recurrence risk after an infection-associated first venous thrombosis.
Limitations
Some potential limitations should be mentioned as well. First, we had data on antibiotic use for only half of the patients of the MEGA study, as only half of the patients could be linked to the SFK registry. Linkage was based on age, sex, 4-digit postal code and anticoagulant use in the month after venous thrombosis, which did not lead to a unique match with a Dutch citizen for more than 54% of the patients. However, clinical characteristics of patients linked or not linked to the SFK registry were similar, suggesting no bias because of this limitation. Second, our results may not be generalizable to all types of infection because we did not have data on antibiotic use during hospital stays, or on viral infections. It is possible that some of the reported antibiotic use was prescribed after discharge from an infection-related hospital stay. However, results for patients with an unprovoked first venous thrombosis (no immobilisation >3 days prior) and for patients with a provoked first venous thrombosis (not related to recent hospitalisation) clearly showed increased risks during antibiotic use. Furthermore, we could not be sure whether antibiotics were prescribed for a known bacterial infection and whether the patient took the medication as prescribed. Given that this could only have led to an underestimation of our results this possible limitation does not explain our findings. Third, as cancer might increase the risk of both infections and venous thrombosis a diagnosis of cancer could account for some of the associations we observed. However, the results for patients with an unprovoked first venous thrombosis (in whom no patients with cancer were present) were in line with those for total venous thrombosis. Therefore, cancer does not explain our findings. Fourth, although we have used the SCCS method to study the association between antibiotic use and first venous thrombotic events, in which fixed confounders do not play a role, transient confounders might have accounted for some of the association we observed. Fifth, in our analyses on recurrent venous thrombosis we were, because of small numbers, unable to correct for additional variables besides age and sex, and residual confounding factors might have played a role in the association we found there. Of note, by using the SCCS and timedependent Cox regression analysis designs we have not been able to dissect the ultimate causal factor for the associations found. To answer such a questions other (experimental) study designs are needed.
Clinical utility of our findings
Our results increase awareness in clinicians of the risk of venous thrombosis in patients during infectious disease. Furthermore, a transient provoking factor for venous thrombosis is defined in the literature as an environmental factor that occurred shortly before the event, that resolves after the event and is associated with a decline in subsequent venous thrombosis risk (Kearon et al, 2016b) . Our findings show that antibiotic use, as a proxy for transient infection, fulfils these criteria and we therefore suggest that antibiotic use (for treatment of infectious disease) should be classified as a transient provoking risk factor for venous thrombosis, which would imply that short-term anticoagulant treatment is sufficient in these patients (Kearon et al, 2012 (Kearon et al, , 2016a .
Conclusion
Individuals who receive antibiotics, which we considered as a proxy for infection, have an approximately three-fold increased risk of a first venous thrombotic event and a twofold increased risk of recurrent venous thrombosis. Patients with an 'unprovoked' first venous thrombosis who had used antibiotics shortly before the event did not have an increased risk of recurrence as compared with patients with a provoked first venous thrombosis. Our results should increase awareness in clinicians of the risk of venous thrombosis in patients with infections. Future clinical trials are required to determine whether patients with prior venous thrombosis who use antibiotics should or should not receive thromboprophylaxis during the infection to decrease their risk of recurrence. Furthermore, accuracy of treatment strategies may be improved by including venous thrombosis associated with a transient infection in the current definition of 'provoked' events.
